FDA Approves Tremfya for Active Crohn Disease in Adults

J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

zacks.com - 21/Mar 12:28

FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.

J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

zacks.com - 21/Mar 12:28

FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

drugs.com - 26/Mar 19:03

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 26, 2025-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has...

FDA Approves Novartis Drug for Rare Kidney Disease Treatment

zacks.com - 21/Mar 18:10

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.

FDA Approves Novartis Drug for Rare Kidney Disease Treatment

zacks.com - 21/Mar 18:10

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.

FDA Approves Blujepa (gepotidacin) for the Treatment of Uncomplicated Urinary Tract Infections

drugs.com - 25/Mar 18:03

London, UK -- 25 March 2025 -- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Blujepa...

Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy

drugs.com - 21/Mar 01:03

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval...

Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy

drugs.com - 21/Mar 01:03

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval...

FDA Approves Blujepa for Uncomplicated Urinary Tract Infections

drugs.com - 25/Mar 21:01

TUESDAY, March 25, 2025 -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract...

FDA Approves Blujepa for Uncomplicated Urinary Tract Infections

drugs.com - 25/Mar 21:01

TUESDAY, March 25, 2025 -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract...

Rubriques :

FDA Approves Tremfya for Active Crohn Disease in Adults

Articles similaires

J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

FDA Approves Novartis Drug for Rare Kidney Disease Treatment

FDA Approves Novartis Drug for Rare Kidney Disease Treatment

FDA Approves Blujepa (gepotidacin) for the Treatment of Uncomplicated Urinary Tract Infections

Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy

Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy

FDA Approves Blujepa for Uncomplicated Urinary Tract Infections

FDA Approves Blujepa for Uncomplicated Urinary Tract Infections

Les derniers communiqués